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Background
Although the prevalence of allergy and incidence of ana-
phylaxis are rising globally, there exists a paucity of data as
to the economic burden of anaphylaxis. This inquiry
reports the estimated magnitude of national fiscal outlays
(direct and indirect) in the United States (US), and inten-
sity of demand by health service area.
Methods
We employed Monte-Carlo simulation, a decision-analyti-
cal framework parameterized by stochastic and determi-
nistic components, to yield a national (US) burden of
illness profile for anaphylaxis. Findings are based on the
US population in 2010, and are reported in 2010 dollars
(US). The prevalence of the at-risk population by type of
exposure (food; insects; medication; latex), resulting use of
health services (direct costs), and death, were discerned
from national survey data from the US National Center
for Health Statistics, and the medical literature. Indirect
costs included lost productivity (earnings), for both
patients and caregivers, and mortality. The methodology
used in this study is applicable on an international basis.
Results
In 2010, the estimated US population at risk for anaphy-
laxis ranged between 3.7 and 48.7 million (median = 14.4
million). The estimated incidence of anaphylaxis ranged
between 50,446 and 657,330 (median = 211,874). Direct
expenditures ranged between $288 million and $3.7 billion
(median = $1.2 billion). Indirect expenditures ranged
between $145 million and $1.9 billion (median = $609 mil-
lion). The point-estimate for direct expenditures for epi-
nephrine was $294 million. Net of the point-estimate for
direct expenditures of epinephrine, and accounting for
biphasic anaphylaxis, both direct and indirect expenditures
far exceeded the expenditure of equipping at-risk patients
with epinephrine autoinjectors.
Conclusions
The extent of under-diagnosis and under-reporting of ana-
phylaxis in the US precludes an exacting measure of the
burden of illness. Our results suggest the burden of illness
due to anaphylaxis in the US is far greater than previously
reported. Similar results may apply internationally.
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